Cardiology

Top Story

FDA rejects hyperkalemia treatment due to manufacturing issue

May 27, 2016

AstraZeneca announced that it received a complete response letter from the FDA indicating that sodium zirconium cyclosilicate will not be approved at this time due to results from a manufacturing inspection.

Sodium zirconium cyclosilicate (ZS-9; AstraZeneca/ZS Pharma) is a novel treatment for hyperkalemia that has potential for use in patients with HF who need to take renin-angiotensin-aldosterone system inhibitors but cannot because of their association with hyperkalemia.

Meeting News Coverage

Blacks, men, youth more likely to receive neuroimaging

May 27, 2016
Patients admitted to the hospital for a stroke are more likely to receive neuroimaging if they are black, male or aged younger than 55 years, according to data presented…
Meeting News CoverageVideo

VIDEO: NLA president highlights initiative to prevent obesity

May 27, 2016
NEW ORLEANS — In this video, Joyce Ross, MSN, CRNP, CLS, FNLA, president of the National Lipid Association, discusses a workshop providing assistance to patients…
In the Journals

DCB yields better results than PTA for femoropopliteal occlusive disease

May 26, 2016
In patients with femoropopliteal occlusive disease, drug-coated balloons appear to be superior to percutaneous transluminal angioplasty, according to results of the…
Meeting News Coverage

BRAVO-3 MRI: Silent emboli common after TAVR, may be linked to stroke

May 26, 2016
A high rate of clinically silent cerebral embolization exists after transcatheter aortic valve replacement, with intraprocedural anticoagulation choice making no…
More News Headlines »
morganatic-roan
morganatic-roan